In a way, my discovery of GLP-1 at Massachusetts General Hospital in Boston was a continuation of what I did at Rockefeller
This slowing contributes to the appetite suppression that drives weight loss and the postprandial glucose-lowering effect, and it also drives most of the gastrointestinal side effect profile.[1],[2] A 2025 review in the Journal of Clinical Endocrinology & Metabolism summarizes the published evidence: GLP-1 receptor agonists impact gastric, intestinal, and gallbladder motility simultaneously, with effects on gastric fundus relaxation, antral contractility inhibition, increased pyloric tone, and reduced small intestinal motility.[3] The path from this mechanism to constipation is straightforward
Among women with a history of GLP-1 RA use, the mean maternal age was 34 years, with a mean body mass index (BMI) of 36
A 2025 analysis including a total of 182 participants with binge eating disorder concluded the same, attributing the effect to how GLP-1s influence brain processes around hunger and reward